HDAC8: a multifaceted target for therapeutic interventions
Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, H...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2015
|
| In: |
Trends in pharmacological sciences
Year: 2015, Jahrgang: 36, Heft: 7, Pages: 481-492 |
| ISSN: | 1873-3735 |
| DOI: | 10.1016/j.tips.2015.04.013 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.tips.2015.04.013 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0165614715000899 
|
| Verfasserangaben: | Alokta Chakrabarti, Ina Oehme, Olaf Witt, Guilherme Oliveira, Wolfgang Sippl, Christophe Romier, Raymond J. Pierce, Manfred Jung |
| Zusammenfassung: | Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major ‘epigenetic player’ that is linked to deregulated expression or interaction with transcription factors critical to tumorigenesis. In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection. The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors. Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions. |
|---|---|
| Beschreibung: | Gesehen am 30.03.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1873-3735 |
| DOI: | 10.1016/j.tips.2015.04.013 |